ImmunityBio Overview
Latest ROE for ImmunityBio: 94.89% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow94.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
ImmunityBio (IBRX) currently reports a ROE of 94.89%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore ImmunityBio's ROE history and peer comparisons.
ImmunityBio's ROE of 94.89% is higher than the Healthcare sector average of 22.01%. That is roughly 331.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but ImmunityBio's current 94.89% should be judged against Healthcare norms (sector average: 22.01%) and against IBRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 94.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for ImmunityBio, and consider following IBRX for alerts when major investors trade the stock.
ImmunityBio is classified in the Healthcare sector. On ROE, it currently shows 94.89% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBRX with unrelated industries.
